Journal of Immunology Research 2022

6 papers
The 2022 volume of the Journal of Immunology Research focused on tumor immunology, clinical transplantation, and cardiovascular inflammation. A significant portion of the research explored the role of specific biomarkers and immune subtypes in predicting prognosis and understanding the tumor microenvironment for conditions such as esophageal squamous cell carcinoma, lung adenocarcinoma, and osteosarcoma. These studies examined mechanisms like SCARA5 expression and circulating tumor cell-related risk models to assess immune infiltration and cancer progression. Other research directions included therapeutic interventions and clinical management strategies. One study investigated the use of artemisinin to inhibit myeloid-derived suppressor cells, potentially enhancing anti-PD-L1 immunotherapy in melanoma and liver tumors. Clinical research also addressed the prediction of tacrolimus concentrations in kidney transplant recipients through genetic and clinical factors. Additionally, the journal featured work on the role of PCSK9 in modulating macrophage polarization during ventricular remodeling after myocardial infarction. Prolific contributors to the year's publications included researchers such as Bingzhang Qiao, Haiping Zhang, and Liwei Zhang.

Top Research Directions

The 24 research directions with Journal of Immunology Research 2022 papers, ranked by paper count, next to 2021. Share is the fraction of the edition’s papers in the direction.

#Direction20222021Share 2022Share 20212021 rank
1Bridging the Cross Species Clinical Translation Gap2033.3%0.0%—
2Therapeutic Suppression of the NF-κB and NLRP3 Pathways2033.3%0.0%—
3Characterizing Immune Infiltration via Single-Sample Gene Set Enrichment Analysis1016.7%0.0%—
4Computational Deconvolution of the Tumor Microenvironment1016.7%0.0%—
5Cross Dataset Validation for Robust Model Generalization1016.7%0.0%—
6Evaluating Clinical Outcomes Using Historical Patient Cohorts1016.7%0.0%—
7Identifying Molecular Vulnerabilities for Tumor Growth Suppression1016.7%0.0%—
8In Vivo Xenograft Models for Preclinical Cancer Research1016.7%0.0%—
9Interpreting Gene Expression via Functional Enrichment Analysis1016.7%0.0%—
10Mitigating the Paradoxical Damage of Tissue Reperfusion1016.7%0.0%—
11Multicellular Ecosystems and Ecotypes in the Tumor Microenvironment1016.7%0.0%—
12Overcoming the Immunosuppressive Tumor Microenvironment1016.7%0.0%—
13Overcoming Tissue Sampling Bias via Quantitative Radiomics1016.7%0.0%—
14Quantifying Gene Expression with Real-Time PCR1016.7%0.0%—
15Quantifying Immune Cell Infiltration for Cancer Prognosis1016.7%0.0%—
16Quantifying Ventricular Function and Hemodynamic Performance1016.7%0.0%—
17Quantitative Histomorphometry for Assessing Tissue Structural Remodeling1016.7%0.0%—
18Remodeling the Tumor Microenvironment with Combination Immunotherapy1016.7%0.0%—
19Reprogramming Macrophage Phenotypes in the Tumor Microenvironment1016.7%0.0%—
20Reprogramming Macrophage Polarization for Tissue Repair1016.7%0.0%—
21The Context Dependent Duality of Cancer Signaling1016.7%0.0%—
22The Sustainability Gap in Short-Term Clinical Evaluations1016.7%0.0%—
23Time Dependent ROC Analysis for Survival Forecasting1016.7%0.0%—
24Transcriptomic Signatures for Cancer Risk Stratification1016.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Immunology Research 2022 papers: a paper credits every institution named in its affiliations, once. 16 institutions share 6 credited papers.

#InstitutionPapersShare20212021 rank
1Jinan University 233.3%0—
202qx1ae98 116.7%0—
302yd1yr68 116.7%0—
403dveyr97 116.7%0—
5056swr059 116.7%0—
6Chinese Academy of Sciences 116.7%0—
7Chinese University of Hong Kong 116.7%0—
8Guangxi University 116.7%0—
9Huazhong University of Science and Technology 116.7%0—
10Hunan Normal University 116.7%0—
11La Trobe University 116.7%0—
12Shenzhen Children's Hospital 116.7%0—
13Shenzhen Institutes of Advanced Technology 116.7%0—
14Tongji University 116.7%0—
15University of Chinese Academy of Sciences 116.7%0—
16University of Verona 116.7%0—

Download all institutions as CSV

About this data

Papers. Journal of Immunology Research 2022 lists 6 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2021 use shares, since the edition went from 2 to 6 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 6 of 6 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Immunology Research 2022”, https://lacuna.tiptreesystems.com/venue/journal-of-immunology-research/2022.

Top Authors

AuthorPapers
Qingfeng Chen1

Impactful Papers

Papers from Journal of Immunology Research 2022 that shaped research clusters.

Foundational

Influential

Papers

Title
Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma
Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma
Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma
PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction
Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection
Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumor